News and Events
News and Events
April 25, 2011
CiRA and DSP Research the Creation of a New Treatment for Rare Intractable Diseases
The Center for iPS Cell Research and Application (CiRA), Kyoto University (Location: Kyoto; Director: Shinya Yamanaka) and Dainippon Sumitomo Pharma Co., Ltd. (DSP; Headquarters: Osaka, Japan; President: Masayo Tada) announce the signing of an agreement for 5 years of joint research with the aim to create treatment for a rare intractable disease.
This joint research collaboration between industry and academia, focusing on a rare intractable disease caused by genetic mutation, aims to use induced pluripotent stem cells (iPS cells) to identify the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various pathological changes of signal transduction, and screen specific inhibitors against the signal pathway. As a result, the aim is to create an epoch-making treatment to suppress detrimental conditions in patients.
[Joint Research Outline]
Research Period: March 2011 – March 2016 (5 Years)
(DSP) To synthesize, evaluate and optimize candidate compounds, and develop the treatment for the disease found through the joint research .
[About the Center for iPS Cell Research and Application (CiRA), Kyoto University]
Established on April 1, 2010, CiRA is a world-first core institute dedicated to leading iPS cell research. CiRA has a system to promote the seamless translation of fundamental research to preclinical and clinical applications.
Location: 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Director: Shinya Yamanaka, M.D., Ph.D.
[About Dainippon Sumitomo Pharma Co., Ltd.]
Dainippon Sumitomo Pharma supplies REPLAGAL®, the therapeutic agent for Anderson–Fabry disease, and is progressing the development of WT1 cancer peptide vaccine "WT4869" aiming for treatment of Myelodysplastic syndrome (MDS). DSP works on the continued development of treatment for rare diseases.
Location: Osaka, Japan.
President: Masayo Tada